PBYI (Puma Biotechnology, Inc.) Stock Financials & Earnings | Market Cap Arena

PBYI (Puma Biotechnology, Inc.) Stock Financials & Earnings | Market Cap Arena

PBYIPuma Biotechnology, Inc.

Mkt Cap$311M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$228M

Net Income (TTM)$31M

EPS (TTM)$0.61

Free Cash Flow (TTM)$48M

Gross Margin74.5%

Op. Margin16.3%

Net Margin13.6%

FCF Margin21.2%

P/S Ratio (TTM)1.4x

P/E Ratio (TTM)10.0x

YoY Rev Growth-0.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$53M	$40M	$4M
Q2 23	$55M	$43M	$5M
Q3 23	$56M	$43M	$9M
Q4 23	$72M	$48M	$15M
Q1 24	$44M	$33M	-$2M
Q2 24	$47M	$36M	-$2M
Q3 24	$81M	$51M	$22M
Q4 24	$59M	$45M	$13M
Q1 25	$46M	$35M	$4M
Q2 25	$52M	$40M	$7M
Q3 25	$54M	$42M	$10M
Q4 25	$76M	$52M	$17M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	1.3x	64.8x
Q2 23	1.4x	—
Q3 23	1.4x	83.8x
Q4 23	1.3x	14.4x
Q1 24	1.4x	20.3x
Q2 24	1.4x	35.7x
Q3 24	1.3x	13.4x
Q4 24	1.4x	10.3x
Q1 25	1.3x	8.2x
Q2 25	1.3x	6.4x
Q3 25	1.5x	8.4x
Q4 25	1.4x	10.0x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$3M	-$10M
Q2 23	$3M	$3M
Q3 23	$11M	$11M
Q4 23	$10M	$10M
Q1 24	$11M	$11M
Q2 24	$1M	$1M
Q3 24	$11M	$11M
Q4 24	$16M	$16M
Q1 25	$4M	$4M
Q2 25	$14M	$14M
Q3 25	$10M	$10M
Q4 25	$21M	$21M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$13M
Q2 23	$68K
Q3 23	$27K
Q4 23	$45K
Q1 24	$0
Q2 24	$20K
Q3 24	$20K
Q4 24	$16K
Q1 25	$61K
Q2 25	$20K
Q3 25	$26K
Q4 25	$142K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+15.4%	+4.1%
Q2 23	-8.3%	+4.7%
Q3 23	-1.7%	-13.1%
Q4 23	+9.9%	+3.1%
Q1 24	-17.1%	-4.8%
Q2 24	-13.7%	-0.8%
Q3 24	+43.5%	+23.0%
Q4 24	-18.2%	-20.3%
Q1 25	+5.1%	-8.8%
Q2 25	+11.4%	-7.0%
Q3 25	-32.4%	-23.2%
Q4 25	+27.8%	+27.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	5.4%
Q2 23	$2M	4.5%
Q3 23	$3M	4.5%
Q4 23	$2M	3.4%
Q1 24	$2M	5.4%
Q2 24	$2M	4.4%
Q3 24	$2M	2.6%
Q4 24	$2M	3.0%
Q1 25	$2M	4.4%
Q2 25	$2M	3.1%
Q3 25	$2M	3.1%
Q4 25	$6M	7.5%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$13M	$22M	—	—
Q2 23	$13M	$24M	—	—
Q3 23	$11M	$22M	—	—
Q4 23	$13M	$20M	$367K	—
Q1 24	$14M	$22M	$110K	—
Q2 24	$14M	$25M	—	—
Q3 24	$13M	$17M	—	—
Q4 24	$15M	$17M	—	—
Q1 25	$14M	$17M	—	—
Q2 25	$15M	$18M	—	—
Q3 25	$16M	—	—	$17M
Q4 25	$17M	—	—	$18M

Revenue Segments

Quarter	Product	Royalty
Q1 23	$47M	$6M
Q2 23	$52M	$3M
Q3 23	$52M	$5M
Q4 23	$53M	$19M
Q1 24	$40M	$3M
Q2 24	$44M	$3M
Q3 24	$56M	$24M
Q1 25	$43M	$3M
Q2 25	$49M	$3M
Q3 25	$52M	$3M
Q4 25	$60M	$16M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$61M	$10M	$71M
Q2 23	$60M	$14M	$74M
Q3 23	$82M	$3M	$85M
Q4 23	$85M	$11M	$96M
Q1 24	$77M	$30M	$107M
Q2 24	$67M	$30M	$97M
Q3 24	$67M	$29M	$97M
Q4 24	$69M	$32M	$101M
Q1 25	$63M	$30M	$93M
Q2 25	$55M	$41M	$96M
Q3 25	$54M	$41M	$94M
Q4 25	$30M	$68M	$98M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	47M	+2.9%
Q2 23	47M	+0.1%
Q3 23	48M	+1.3%
Q4 23	48M	+0.5%
Q1 24	48M	+0.3%
Q2 24	48M	+0.2%
Q3 24	49M	+1.8%
Q4 24	49M	+0.5%
Q1 25	50M	+1.0%
Q2 25	50M	+0.5%
Q3 25	51M	+1.6%
Q4 25	52M	+1.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$0	120
FY 15	$0	156
FY 16	$0	160
FY 17	$87K	318
FY 18	$923K	272
FY 19	$1M	269
FY 20	$843K	267
FY 21	$1M	196
FY 22	$1M	192
FY 23	$1M	185
FY 24	$1M	172
FY 25	$7K	33K